Rhinitis, Allergic, Perennial
Pipeline by Development Stage
On Market (14)
Approved therapies currently available
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 35 trials with date data
Clinical Trials (35)
Total enrollment: 16,279 patients across 35 trials
A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
Fluticasone Nasal Spray Patient Preference Study
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)
Long Term Safety Of GW685698X Via Nasal Biopsy
Perennial Allergic Rhinitis In Pediatric Subjects
Study Of Perennial Allergic Rhinitis In Pediatrics
Seasonal Allergic Rhinitis In Pediatric Subjects
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
Perennial Allergic Rhinitis Study In Pediatric Subjects
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis
WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis
Repeated Dosing Clinical Trial of HL151
Single Dosing Clinical Trial of HL151
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Flixonase Safety in Patients With Allergic Rhinitis (AR)
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.